Synergistic action of CB

Animals Benzoxazines / pharmacology Calcium Channel Blockers / pharmacology Male Morpholines / pharmacology Muscarinic Agonists / toxicity Naphthalenes / pharmacology Pilocarpine / toxicity Rats Rats, Sprague-Dawley Receptor, Cannabinoid, CB1 / drug effects Receptor, Serotonin, 5-HT2B / drug effects Serotonin 5-HT2 Receptor Agonists / pharmacology Status Epilepticus / chemically induced
Cannabinoid receptors Clinical applications EEG Endocannabinoid system Serotonin Status epilepticus Synergistic interactions

Journal

Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169

Informations de publication

Date de publication:
05 2019
Historique:
received: 30 10 2018
revised: 24 01 2019
accepted: 31 01 2019
pubmed: 5 2 2019
medline: 18 12 2019
entrez: 5 2 2019
Statut: ppublish

Résumé

Endocannabinoids (eCBs) and serotonin (5-HT) play a neuromodulatory role in the central nervous system. Both eCBs and 5-HT regulate neuronal excitability and their pharmacological potentiation has been shown to control seizures in pre-clinical and human studies. Compelling evidence indicates that eCB and 5-HT systems interact to modulate several physiological and pathological brain functions, such as food intake, pain, drug addiction, depression, and anxiety. Nevertheless, there is no evidence of an eCB/5-HT interaction in experimental and human epilepsies, including status epilepticus (SE). Here, we performed video-EEG recording in behaving rats treated with the pro-convulsant agent pilocarpine (PILO), in order to study the effect of the activation of CB

Identifiants

DOI: 10.1016/j.nbd.2019.01.026 PMID: 30716469
pubmed: 30716469
pii: S0969-9961(19)30033-6
doi: 10.1016/j.nbd.2019.01.026
pii:
doi:

Substances chimiques

Benzoxazines 0
Calcium Channel Blockers 0
Morpholines 0
Muscarinic Agonists 0
Naphthalenes 0
Receptor, Cannabinoid, CB1 0
Receptor, Serotonin, 5-HT2B 0
Serotonin 5-HT2 Receptor Agonists 0
Pilocarpine 01MI4Q9DI3
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone 5H31GI9502

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-145

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Roberto Colangeli (R)

Laboratory of Neurophysiology, Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida, Malta. Electronic address: roberto.colangeli@ucalgary.ca.

Roberto Di Maio (R)

Pittsburgh Inst. for Neurodegenerative Dis., Dept. of Neurology, Univ. of Pittsburgh, PA, USA.

Massimo Pierucci (M)

Laboratory of Neurophysiology, Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida, Malta.

Gabriele Deidda (G)

Laboratory of Neurophysiology, Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida, Malta.

Maurizio Casarrubea (M)

Department of Experimental Biomedicine and Clinical Neurosciences, Human Physiology Section "Giuseppe Pagano", University of Palermo, Palermo, Italy.

Giuseppe Di Giovanni (G)

Laboratory of Neurophysiology, Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida, Malta; School of Biosciences, Cardiff University, Cardiff, UK. Electronic address: giuseppe.digiovanni@um.edu.mt.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Synergistic action of CB
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzoxazines › Synergistic action of CB
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents cardiovasculaires › Inhibiteurs des canaux calciques › Synergistic action of CB
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Oxazines › Morpholines › Synergistic action of CB
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents cholinergiques › Agonistes cholinergiques › Agonistes muscariniques › Synergistic action of CB
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Naphtalènes › Synergistic action of CB
questionsmedicales.fr › Composés hétérocycliques › Alcaloïdes › Pilocarpine › Synergistic action of CB
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Synergistic action of CB
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Rat Sprague-Dawley › Synergistic action of CB
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteurs de cannabinoïdes › Récepteur cannabinoïde de type CB1 › Synergistic action of CB
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs sérotoninergiques › Récepteurs de la sérotonine de type 5-HT2 › Récepteur de la sérotonine de type 5-HT2B › Synergistic action of CB
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents sérotoninergiques › Agonistes des récepteurs de la sérotonine › Agonistes des récepteurs 5-HT2 de la sérotonine › Synergistic action of CB
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Crises épileptiques › État de mal épileptique › Synergistic action of CB